Company / Net Income
Aclaris Therapeutics, Inc. Net Income History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$64.9M
FY2025
5-year range
-$90.9M / -$64.9M
FY2021-FY2025
Trend
+26.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income has fluctuated over the past 9 years, ranging from -$133M in FY2020 to -$21M in FY2017.
Based on SEC 10-K filings.
-$65M in FY2025.
Improved from -$91M to -$65M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, net income increased 26.6% year-over-year.
- Peak net income was recorded in FY2017.
- Lowest net income in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$64.9M | +26.6% |
| FY2024 | -$88.5M | +2.6% |
| FY2023 | -$90.9M | -4.6% |
| FY2022 | -$86.9M | +4.4% |
| FY2021 | -$90.9M | +31.5% |
| FY2020 | -$132.7M | -93.7% |
| FY2019 | -$68.5M | +48.4% |
| FY2018 | -$132.7M | -545.5% |
| FY2017 | -$20.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026